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Experience with Biosynthetic Human Insulin in Diabetest 
Davida F. Kruger, MSN,* Fred W. Whitehouse, MD,* 
Dorothy M. Kahkonen, MD,* jean O. Partamian, MD,* 
J.David Fachnie, MD,* Jos^ Goldman, MD, PhD,* and David Leach, MD** 
Thirty diabetic patients new to insulin were entered in 
an open label prospective study of biosynthetic human 
insulin (BHI). All patients experienced symptomatic con-
trol of diabetes attributable to dietary and BHI insulin 
therapy. Detailed six-month evaluation data were review-
ed in 19 patients. A significant drop in fasting plasma 
glucose and glycosylated hemoglobin was noted at two 
months, and a further modest decrease occurred at six 
months. E. coli polypeptide antibodies were unchanged 
from baseline at six months, indicating that no bacterial 
protein contamination of BHI occurred. Percent binding 
of serum antibodies to human insulin measured in 19 
patients at baseline and at six months showed a statisti-
cally significant increase in mean value without accom-
panying clinical symptoms. Clinical hypoglycemia did 
not differ from that seen in patients who received animal 
insulin. Biosynthetic human insulin appears comparable 
in clinical efficacy and safety to purified pork insulin. 
Ongoing studies will be required to determine whether 
BHI is less immunogenic than purified pork insulin. 
Research on the chemical analysis of insulin was first 
reported in 1959 when Sanger described the amino acid 
sequence of animal insulin (1). One year later, Nicol and 
Smith reported on the amino acid sequence of human 
insulin (2). In the next decade, investigators in the 
United States, West Germany, and China chemically syn-
thesized insulin. While the primary amino acid structure 
of human, beef, and pork insulins varies only slightly 
from each other (Table I), this difference is sufficient to 
produce a significant immunogenic effect, especially 
with beef insulin, in which the amino acid sequence 
varies from human insulin by three amino acids. Although 
human and pork insulins are nearly identical, an anti-
body response will occur when pork insulin is injected 
into diabetic humans. Nevertheless, highly puri f ied, 
unmodif ied pork insulin is the least immunogenic of 
animal insulins. Reasonably, human insulin might be 
wi thout antigenic effect when injected into a homolo-
gous host. Except for the lack of automatic influence on 
changing blood glucose levels, injected human insulin 
should be the best therapy for the insul in-requir ing dia-
betic patient. 
Human insulin has been produced both by a recombi-
nant DNA process (3) and by a semisynthetic technique. 
In the latter technique, by enzymatic transpeptidation, 
the amino acid threonine is substituted fora lan ineat the 
TABLE I 
COMPARATIVE PARTIAL A M I N O ACID 
STRUCTURE OF A N I M A L A N D H U M A N INSULIN 
Insul in* A chain B chain 
Position 8 9 10 30 
Beef Ala Ser Val Ala 
Pork Thr Ser llu Ala 
Human Thr Ser llu Thr 
*AII other amino acids on A and B chain are identical between species. 
B30 position of the insulin molecule (4). The chemical 
and biologic properties of biosynthetic human insu-
lin (BHI) are identical to those of pancreatic human 
insulin (5). Pharmacologically pure, BHI matches animal 
insulin in biologic action, yielding a prompt fa l l in blood 
glucose after intravenous or subcutaneous injection (6). 
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TABLE II 
DEMOGRAPHIC DATA O N 30 DIABETIC PATIENTS 
Age: 21-85 years (mean: 56 years) 
Sex: Male: 11 
Female: 19 
Race: Whi te : 17 
Black: 13 
Type of Diabetes: Insul in-dependent: 1 
Non- insul in-dependent : 27 
Secondary: 2 
Durat ion of Diabetes: 0-26 years (mean: 5.6 years) 
Percent of Ideal Body Weight: At onset: 134 + 28 
At six months: 143 ± 31 
Immunologically, however, BHI presented a conun-
drum before it was in clinical use for human diabetes. 
Would a homologous protein be immunogenic? Since 
endogenous human insulin secreted into the pancreatic 
venous eff luent lacks antigenicity, does the manufactur-
ing process necessary to produce BHI create immu-
nogenicity? Would human insulin injected subcutane-
ously stimulate antibody production? 
To explore the clinical efficacy and safety of human 
insulin, to investigate its immunogenic potential, and as 
part of a mult i-center clinical tr ial, we initiated an open 
label prospective study of BHI in insulin-requir ing dia-
betic patients in 1981. 
Materials and Methods 
Thirty diabetic patients new to insulin were recruited 
over a six-month period (Table II). All patients had symp-
toms and signs of uncontrol led diabetes when therapy 
began. The serum of each patient was free of proinsulin 
antibodies, substantiating the absence of prior use of 
exogenous insulin. Before admission to the study, the 
patient or a family member signed a detailed informed 
consent form. 
Baseline studies included analyses on the state of meta-
bolic imbalance (blood and urine for glucose, serum 
C-peptide levels, total glycosylated hemoglobin); immuno-
logic responsiveness (islet cell antibodies and immune 
complexes, circulating insulin antibodies [7], E. coli poly-
peptide antibodies [8], and proinsulin antibodies); and 
parenchymal organ funct ion (complete blood count 
and multichannel serum chemistry tests). As described 
elsewhere, intradermal testing was performed at base-
line and after six months of treatment with BHI. The 
double-bl ind test kit consisted of human insulin in 
increasing concentrations plus positive and negative 
controls (9). 
After insulin therapy began, patients were checked 
monthly for two months, then bimonthly thereafter up 
to the present (26 months). The diabetes in these 
patients was managed with a dietary prescription appro-
priate to weight, physical activity, and sufficient insulin 
to establish and maintain metabolic control . Study 
patients received either human neutral regular insulin 
(NRI), human isophane (NPH) insulin, or both as indi-
vidually required. 
At each clinic visit, a thorough history was taken and a 
physical assessment was made. To monitor metabolic 
control of the diabetes, each patient regularly per-
formed self-testing of blood glucose using an Ames dex-
trometer. Fasting and stimulated blood glucose levels 
and glycosylated hemoglobin values were measured at 
each visit. 
We have six-month evaluation data on 19 of 30 patients in 
the study. Ten of the 19 received NRI daily along with 
NPH insulin. Other patients have received NRI from time 
to time to correct isolated episodes of hyperglycemia. 
Four patients were dropped f rom the study. Two inad-
vertently received animal insulin, one patient chose to 
stop insulin because of hypoglycemia, and a fourth 
patient died of natural causes. 
Results 
All patients experienced symptomatic control of diabetes 
attributable to dietary therapy and insulin replacement. 
Mean weight increased significantly over a six-month 
period from 134% to 143% of ideal weight (Table II). 
Complete blood counts, blood chemistry tests, and ur in-
alyses were unchanged except for glycosuria and keto-
nuria. While 18 of 19 patients had fasting glycosuria, and 
11 of 19 had fasting ketonuria at baseline, no patient had 
either fasting glycosuria or ketonuria when examined six 
months later. No data are available on serum lipids. 
Plasma glucose concentration was significantly reduced 
wi th in two months after insulin was started. A further 
modest decrease was noted at six months (Table III). 
Mean fasting C-peptide levels in 19 patients declined 
f rom 0.84 pmoles/ml at baseline to 0.79 pmoles/ml at 
latest assessment. Islet cell antibodies were negative in 
15 of 16 patients, although slight fluorescence was noted 
in one patient. No significant immune complexes were 
demonstrated in these 16 patients. E. coli polypeptide 
antibodies were unchanged from baseline when patients 
were reexamined at six months (101 ± 44 vs 103 ± 76 
counts/minute; p value = 0.90). No changes occurred in 
intradermal tests. 
Percent binding of serum antibodies to human insulin 
measured in 19 patients at baseline and at six months 
73 
Kruger, Whitehouse, Kahkonen, Partamian, Fachnie, Goldman, and Leach 
showed a statistically significant increase in mean value 
(1.48 ± 1.39% vs 5.61 ± 6.54%; p value = 0.020). At 
six months, only five patients had significant levels of 
antibody binding (over 4.3%, mean plus two standard 
deviations). Three of these values were 11.6%, 21.7%, 
and 23.5%. 
Discussion 
Our open label study of 30 diabetic patients who 
received biosynthetic human insulin for up to 26 months 
indicates that it is safe and efficacious. After six months 
of therapy, the daily insulin dose in our patients aver-
aged 42 ± 20 units, a f inding compatible with previous 
experience with animal insulin. Galloway and co-workers 
in shor t - term studies found daily insul in dosages 
unchanged when crossover experiments between BHI, 
pork, and beef-pork insulin were carried out (9). Double-
bl ind, short-term crossover studies in established dia-
betic patients using beef, pork, and biosynthetic human 
insulin have found only subtle differences between 
blood glucose responses to the three insulin prepara-
tions (10). No local reactions to BHI at the site of 
injection occurred in our patients; nor have we identi-
fied patients with subcutaneous insulin l ipohypertrophy 
or lipoatrophy. 
Hypoglycemic reactions were the same as those fol low-
ing the use of animal insulin and did not appear with 
greater or less frequency than expected, except that 
some patients experienced a more rapid onset of blood 
glucose lowering effect of NPH-BHI manifested by mid-
morning or pre-lunch hypoglycemia. In addit ion, these 
patients at times required two injections of NPH-BHI to 
insure normoglycemia before breakfast. Pharmacoki-
netic studies (11) and clinical studies (12,13) have sug-
gested a t ime-action of NPH-BHI that is faster in onset 
and shorter than that of beef-NPH insulin, an observa-
t ion that agrees with our findings. However, this particu-
lar t ime action of NPH-BHI was not seen in most of our 
TABLE III 
FASTING PLASMA GLUCOSE AND GLYCOSYLATED 
HEMOGLOBIN VALUES AT BASELINE, AT SIX MONTHS, 
AND AT LATEST MEASUREMENT 
Baseline (30)* ' 




(mg/d l ) 
363 ± 134 
161 ± 48 
181 ± 70 
Glycosylated 
hemog lob in* 
(%) 
15.2 ± 4 . 2 
9.5 + 2.4 
10.5 ± 2.4 
patients, was easily dealt w i th , and probably relates to 
the ratio of insulin to protamine in the NPH preparations. 
Initial antibody data impute minimal immunogenicity to 
BHI. Because it is homologous, it has been suggested 
that antibodies might not develop. Fineberg and col-
leagues have reported a decrease in qualitative and 
quantitative insulin antibody binding when patients 
previously taking mixed beef-pork insulin have been 
changed either to purif ied pork insulin (PPI) or to BHI 
(7). These investigators also noted small but significant 
decreases in antibody binding in patients changed from 
PPI to BHI. Short-term crossover studies in established 
diabetic patients have suggested little difference between 
PPI and BHI in the concentration of insulin antibodies 
(14). On the other hand, significant differences do occur 
in antibody concentration when beef insulin is changed 
to human insulin, an expected f inding because of the 
greater immunogenici ty of beef insulin. In longer-term 
studies with BHI, Fineberg and colleagues found lower 
antibody levels to insulin in patients on BHI when com-
pared to patients on PPI (15). They noted that no increase 
in antibodies to BHI occurred after six months of ther-
apy. Data available f rom 19 of our patients receiving BHI 
showed a significant rise in human insulin antibody 
binding in five patients at six months. None of these 
TABLE IV 
SERUM INSULIN ANTIBODIES (% BOUND/TOTAL) AFTER BHI USE 
Patient Actual Baseline Time on study (days post-therapy) 
Number Value 15-45 91-150 151-210 
*Normal values (6.0-8.8%) 
* *Number of patients tested 
501 2.9 0.0 0,0 7.2 
503 1.4 0.0 0.2 1.2 
504 1.4 0.0 0.7 4.0 
505 0.2 0.0 0.0 1.3 
506 3.3 0.7 1.9 3.9 
507 0.8 1.3 2.4 11.6 
508 0.0 0.8 1.9 21.7 
509 2,1 0,2 0,5 3.5 
510 0.4 0.0 0.0 1.1 
511 5.2 2.1 4.3 
512 2.0 0.3 1.5 2.4 
513 0.5 0.0 2.1 4,5 
514 2.3 0.2 0.0 3.8 
515 2.7* 2.4 0.2 0.9 
516 0.2 0.0 1.5 23.5 
517 0.6 0,0 0.0 2.7 
518 0.2 0.0 0.0 0.0 
519 0,0 o.c 3,8 3.7 
523 2.0 0.0 3,0 5.8 
*10 days post-therapy 
Summation 
No. of Patients Mean Baseline Last Assessment p Value 
19 1.48 ± 1.39 5.61 ± 6.54 0.020 
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patients manifested clinical findings compatible with 
insulin allergy or resistance. Statistically significant insulin 
antibody binding ranged f rom 5.8% to 23.5%. Raw data 
for each patient and summation data are charted in 
Table IV. Comparable species-specific insulin antibody 
binding in patients receiving pork or mixed beef-pork 
insulin could average two-to-eight- fold higher. Serum 
antibody binding in patients with immunologic insulin 
resistance wil l approach 80-90% (Fineberg, personal 
communicat ion). Longer fo l low-up on these patients 
and others with similar findings wil l be required before 
the clinical significance can be ascertained. Comparing 
BHI immunogenici ty wi th that of PPI remains under 
study; however, longer-term studies suggest that BHI 
may be less immunogenic than PPI (15). The clinical 
significance ofthis observation remains to be elucidated. 
Careful analysis for a possible effect of E. coli antigens 
was carried out in all patients who received BHI. No 
evidence of E. coli polypeptide antibodies was ident i -
f ied. Baseline and six month levels were unchanged. 
Accordingly, concern that a bacterial protein might be 
present as a result of the fermentation process and 
introduced during BHI therapy can be allayed. These 
proteins are eliminated during the insulin purif ication 
processes (9). 
Biosynthetic human insulin controls the symptoms and 
lowers the plasma glucose of patients with insulin-
requir ing diabetes. It is used similarly to the purif ied 
animal insulins in comparable daily dosages. The t ime 
action of NPH-BHI appears to be slightly shorter and to 
have a quicker onset than occurs with NPH derived from 
animal insulin. In the patients we have treated, we have 
not identif ied any with insulin allergy or insulin resist-
ance. Al though we have not treated patients with pre-
existing insulin allergies, others have successfully treated 
such patients (16,17). In our experience, BHI is safe to use 
for the insulin-requiring diabetic patient. 
Current indications for the use of human insulin include: 
1) patients who are allergic to insulin or have chronic 
immunologic insulin resistance; 2) initial insulin admin-
istration to young, insulin-dependent diabetic patients; 
3) patients who require insulin therapy intermittently; 4) 
patients with insulin l ipoatrophy who fail to respond to 
treatment with purif ied pork insulin; 5) as a substitute 
for purif ied pork insulin; and 6) patient or physician 
preference. 
If the long-term use of human insulin yields the lowest 
levels of antibody achievable, human insulin should be 
standard therapy for young insulin-dependent diabetic 
patients. Theoretically, minimal immunogenici ty might 
extend the remission phase of diabetes by protecting 
residual islet cell funct ion. This possibility requires cl ini-
cal documentat ion. Furthermore, significantly lower 
insulin antibody levels might reduce the metabolic labil-
ity that characterizes patients with insulin-dependent 
diabetes. Data on this question remain inconclusive. 
Human insulin should be tr ied in patients who demon-
strate erratic subcutaneous insulin absorption, although 
the mechanism ofthis problem remains unclear and may 
be multifactorial. Finally, the availability of BHI relieves 
the growing fear of insufficient insulin supply, since 
human insulin f rom recombinant DNA sources does not 
depend on the availability of animal pancreas. 
We have no experience with semisynthetic human 
insulin, but we expect no differences between human 
insulin of biosynthetic and semisynthetic sources. Longer-
term studies wil l teach us whether human insulin is pre-
ferred to PPI. Human insulin wil l increase in use just 
because it is an homologous insulin as long as its cost to 
the patient is not prohibit ively high. 
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D i a t e f i c N e u r o p a f l i i c A r t k r o p a f l i y : 
Ckarcot; J o i n i 
Afflicts fewer than 0.5% of diabetic patients 
Diabetes more frequent cause than leprosy or lues 
Progressive subluxation and destruction of 
traumatized joint 
Ninety percent in foot and ankle 
Arterial circulation generally good 
Mid-foot swelling and collapse of longitudinal arch 
Characteristic radiological changes 
- joint distortion 
- fractures 
- bony fragmentation 
- osteoporosis 
- new bone formation 
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Henry Ford Hospital 
Charcot Joint: Radiograph of a case of bilateral Charcot with marked 
destruction of tarsal bones. 
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